|
The use of at-home medical devices to connect doctors and patients via the internet can help patients and their physicians work more efficiently together to manage chronic conditions, according to research at Cleveland Clinic.
On-X LTI Technologies, a heart valve product provider, has entered into a license agreement with the Cleveland Clinic in Ohio to develop a system of surgical tools that will facilitate the replacement process of a severed mitral valve chordate.
Less than one-third of patients hospitalized for heart failure (HF) and participating in a quality improvement registry received a guideline-recommended treatment, aldosterone antagonist therapy, according to a study in the Oct. 21 issue of the Journal of the American Medical Association.
Baptist Health is expanding its cardiovascular surgery program with new hires at the cardiac and thoracic surgical group.
Striking differences in the risk factors for developing heart failure (HF) and patient prognosis exist between men and women. Men and women may also respond differently to treatment, which has raised concerns about whether current practices provide the best care and reinforcing the urgency for sex-specific clinical trials for HF, according to a review article published in the Aug. 4 issue of the Journal of the American College of Cardiology.
BOSTON—Laser-assisted lead removal demonstrated safety and efficacy, based on initial data from the four-year, retrospective LExICon study presented today at the 30th annual scientific sessions of the Heart Rhythm Society (HRS). However, principal investigator Bruce Wilkoff told Cardiovascular Business News that the greatest differentiator in success rates and patient outcomes depends on operator experience.
Written by C.P. Kaiser
Cardiovascular Business invited some of the most prominent physicians in the field of electrophysiology to talk about the current and future state of the subspecialty.
A panel of Cleveland Clinic physicians and scientists selected a top ten list of breakthrough devices and therapies, which were unveiled during Cleveland Clinic's 2008 Medical Innovation Summit last week in Cleveland.
|
GlaxoSmithKline (GSK) has released a 30-page white paper refuting that the recent U.S. Senate report on its diabetes drug Avandia failed “to present an accurate, balanced or complete view of the currently available information on Avandia (rosiglitazone).”
Written by Kaitlyn Dmyterko
In previous research, investigators have found a direct correlation between hospital primary angioplasty volume and mortality rates in STEMI patients, resulting in a volume criteria for provider settings. However, Deepak L. Bhatt, MD, told Cardiovascular Business News that based on the findings of a recent JAMA study, the volume surrogate should be reconsidered as basis for hospital quality.
Lexiscan, the pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI), is well-tolerated and as effective as the current standard, Adenoscan, according to study results presented this week at the 14th Annual Scientific Sessions of the American Society of Nuclear Cardiology (ASNC) in Minneapolis.
The Society of Cardiovascular CT (SCCT) has named Chirapa Puntawangkoon, MD, and Thananya Boonyasirinant, MD, as the winners of the third annual Young Investigator Award.
Patients who have patent foramen ovale (PFO) incidentally discovered and repaired during surgery for a different condition may have an increased odds of postoperative stroke, along with no clear benefit on short-term outcomes or long-term survival, according to a study in the July 15 issue of the Journal of the American Medical Association.
Stanford University School of Medicine in California will be posting the medical- and research-related consulting activities for approximately 1,200 affiliated physicians and faculty on its web site.
At the end of each physician and researcher bio on The Cleveland Clinic web site is a list of any potential conflicting industry relationships—a novel disclosure policy recently begun by the medical institution.
The Cleveland Clinic has made the decision to allow its stent
distribution deal with Boston Scientific to expire, as the choice for
stents in 2008 has broadened by 50 percent.
|